A qualified physiotherapist can identify movement dysfunctions contributing to your pain, prescribe specific exercises for your condition, guide safe return to activity, and address postural and ergonomic factors
The complex I subunit NDUFA10 selectively rescues Drosophila pink1 mutants through a mechanism independent of mitophagy
Sweating disorders For some people, excessive sweating is because of a condition known as hyperhidrosis
GLP-1 Receptor Agonist Market Report 2026 Global Outlook By Drug Class (Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs), By Route Of Administration (Parenteral, Oral), By End Users (Hospitals, Surgical Clinics, Other Users) Market Size, Trends, Strategies, and Forecast to 2035 GLP-1 Receptor Agonist Market Overview GLP-1 Receptor Agonist market size has reached to $14.09 billion in 2025 Expected to grow to $18.32 billion in 2030 at a compound annual growth rate (CAGR) of 5.4% Growth Driver: Surging Diabetes Cases Fuel Growth In Glp-1 Receptor Agonist Market Market Trend: Sustained-Release Glp-1 Receptor Agonists Are Gaining Popularity North America was the largest region in 2025 and Asia-Pacific is the fastest growing region
As more compounds reach market, identifying which works best for each individual becomes possible, potentially optimizing both efficacy and duration
GLP-1 medications were originally developed for type 2 diabetes , but are now also approved for people with obesity or weight-related health conditions
